Quarterly Activity Report and Appendix C

Imagion Biosystems has released their Quarterly Activity Report for the period ended 30 September 2020 and Appendix C. Q3 Highlights Raised $4.7M (after…


Appendix 3Y — Change of Director's Interest Notice

Imagion Biosystems gave ASX information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Read…


Appendix 2A — Fully Paid Ordinary Shares

Imagion Biosystems has submitted "Appendix 2A — Application for quotation of +securities." Read Appendix 2A.


Vesting of Performance Rights

Imagion Biosystems has advised that 2,500,000 performance rights have vested and were issued as ordinary shares to Executive Chairman and CEO Bob Proulx today,…


Notice Pursuant to Section 708(5)(e) of the Corporations Act 2001

Imagion Biosystems gives notice that, on 20 October 2020 the Company issued 2,401,900 fully paid ordinary shares (Shares) in the Company as the result of…


IBX Secures Additional Capital — Shareholders Exercise Options

Imagion Biosystems announced that it has received a total of $143,157 for the exercise of options. Composed of $142,200 for 2,370,000 options exercisable at 6…


Imagion Biosystems Appoints Geoff Hollis as CFO

Imagion Biosystems has appointed Geoff Hollis as Chief Financial Officer. The appointment strengthens the Company’s management and leadership team as the…


HREC Approval for Phase I Study

Imagion Biosystems is pleased to report that it has received approval from the Human Research Ethics Committee (HREC) for the MagSense® HER2 Phase I study…


Issue of Unlisted Performance Options under EIP

Imagion Biosystems today announced "Issue of unlisted performance options under Equity Incentive Plan". Read the announcement.


Appendix 3G

The attached "Appendix 3G: Notification of issue, conversion or payment up of equity +securities" was released to market. View Appendix 3G.